Results of Extraordinary Shareholders Meeting held on March 8, 2023
Results of ExtraordinaryShareholdersMeeting held on March 8, 2023
Paris, France,March10, 2023 – 19:00 CET – The Extraordinary Shareholders Meeting of Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, was held on second convening in Paris on March 8, 2023 and adopted all the resolutions put to the vote with a percentage of favorable votes at around 97 % relating to the granting to the Board of (i) an authorization to reduce the capital in the context of a capital decrease for losses and by reducing the nominal value of the shares from 0.06 euro to 0.02 euro, (ii) an authorization to decide on a reverse stock split and (iii) all the financial delegations submitted to the vote of the Extraordinary Shareholders Meeting1.
Details of the votes are available on the Company's website in the "Shareholder’s General Meeting" section.
About Pixium Vision
Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The Company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.
For more information: http://www.pixium-vision.com/fr
Follow us on @PixiumVision; www.facebook.com/pixiumvision
www.linkedin.com/company/pixium-vision
Contacts
| Pixium Vision Offer Nonhoff Chief Financial Officer investors@pixium-vision.com +33 1 76 21 47 68 | Media Relations LifeSci Advisors Sophie Baumont sophie@lifesciadvisors.com +33 6 27 74 74 49 | Investor Relations LifeSci Advisors Guillaume van Renterghem gvanrenterghem@lifesciadvisors.com +41 76 735 01 31 |
1with the exception of the capital increase reserved for employees (11th resolution) not adopted
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial3.6.2023 23:00:00 CEST | Press release
The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerabilityPositive clinical responses were reported in 8 out of 12 EVX-01 treated patientsHigh-quality neoantigens, predicted by AI technology, were associated with longer progression-free survivalStrong vaccine-specific immune responses were induced in all 12 EVX-01 treated patients Higher EVX-01 dose induced a stronger immune response and was associated with improved clinical outcome COPENHAGEN, Denmark, June 03, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today presented promising clinical data from its EVX-01 Phase 1 dose escalation trial in metastatic melanoma at the 2023 ASCO annual meeting in Chicago, Illinois. The Phase 1 trial successfully met primary endpoints for safety and tolerability of EVX-01 in metastatic melanoma patients
BW Offshore: Short-term contract extension for Espoir Ivoirien3.6.2023 16:39:00 CEST | Press release
Short-term contract extensionfor Espoir Ivoirien BW Offshore has signed a short-term extension for the lease and operation of the FPSO Espoir Ivoirien in order to discuss a potential purchase of the FPSO by the client. The firm period has been extended until 9 June 2023. For further information, please contact: Ståle Andreassen, CFO, +47 91 71 86 55 Anders S. Platou, Head of Corporate Finance & Strategy, +47 99 50 47 40 IR@bwoffshore.com or www.bwoffshore.com About BW Offshore: BW Offshore engineers innovative floating production solutions. The Company has a fleet of 8 FPSOs with potential and ambition to grow. By leveraging four decades of offshore operations and project execution, the Company creates tailored offshore energy solutions for evolving markets world-wide. BW Offshore has around 2,000 employees and is publicly listed on the Oslo Stock Exchange. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
Jobindex A/S meddeler sin hensigt om afnotering og tilbud fra Danielsen 2 ApS til aktionærerne om køb af deres aktier til 1.900 kr. pr. aktie2.6.2023 20:16:00 CEST | pressemeddelelse
Selskabsmeddelelse nr. 6 / 2023 København, Danmark 2. juni 2023 – Jobindex A/S (“Jobindex” eller “Selskabet”), meddeler, at Jobindex i dag har besluttet at lade Selskabets aktier slette fra handel og officiel notering fra Nasdaq First North Growth Market Denmark (“Nasdaq First North”) og bemyndiget adm. direktør Kaare Danielsen til at indgive anmodning herom til Nasdaq Copenhagen A/S inden den 1. oktober 2023 samt at Danielsen 2 ApS (“Tilbudsgiver”) fremsætter et frivilligt ureguleret offentligt købstilbud på 1.900 kr. pr. aktie (det “Offentlige Købstilbud”) til alle aktionærer i Jobindex med undtagelse af Tilbudsgiver og Selskabet for så vidt angår egne aktier. For aktionærerne i Jobindex A/S betyder dette, at man har valget imellem at: Acceptere det Offentlige Købstilbud, der indebærer en præmie på ca. 8,6% ift. lukkekursen pr. 2. juni 2023 og en præmie på ca. 9,7% ift. de sidste 12 handelsdages volumenvægtede gennemsnitskurs (VWAP); ellerFortsætte uændret som aktionær i Jobindex A/S
Nokia Corporation: Repurchase of own shares on 02.06.20232.6.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 2 June 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 02.06.2023 Espoo, Finland – On 2 June 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL362,6953.83CEUX1,1353.84AQEU1,6303.81TQEX1,9403.81Total367,4003.83 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 and end
BlueCat acquires network infrastructure monitoring and automation platform Indeni2.6.2023 19:00:00 CEST | Press release
Customers will gain an enhanced ability to maintain network resiliency TORONTO, June 02, 2023 (GLOBE NEWSWIRE) -- BlueCat Networks, a leading provider of mission-critical network and cloud infrastructure software for reliable and secure DNS, DHCP, and IP address management (collectively known as DDI), announced today that it has acquired Indeni. Moelis & Company acted as financial advisors to BlueCat. Financial terms were not disclosed, and the deal is subject to regulatory approval. Indeni’s platform helps network operations (NetOps) teams assure the health of their network appliances such as firewalls, load balancers, and secure web proxies. It analyzes device configurations, metrics, and logs through deep domain expertise, codified as knowledge. And it alerts administrators about existing and potential issues, using a global, crowd-sourced knowledge base to identify and recommend remediation steps using automation. Customers using Check Point, Palo Alto Networks, Fortinet, F5, and m